Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Comparison of cost-effectiveness of oral rapamycin plus bare-metal stents versus first generation of drug-eluting stents (from the Randomized Oral Rapamycin in Argentina [ORAR] 3 trial).

Rodriguez AE, Palacios I, Rodriguez-Granillo AM, Mieres JR, Tarragona S, Fernandez-Pereira C, Solorzano L, Pauletto R, Serruys PW, Antoniucci D; ORAR-3 investigators.

Am J Cardiol. 2014 Mar 1;113(5):815-21. doi: 10.1016/j.amjcard.2013.11.033. Epub 2013 Dec 13.

PMID:
24528614
2.

Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.

Rodriguez AE, Rodriguez-Granillo AM, Antoniucci D, Mieres J, Fernandez-Pereira C, Rodriguez-Granillo GA, Santaera O, Rubilar B, Palacios IF, Serruys PW; ORAR III Investigators.

Catheter Cardiovasc Interv. 2012 Sep 1;80(3):385-94. doi: 10.1002/ccd.23352. Epub 2011 Dec 8.

PMID:
22109997
3.

Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study.

Rodriguez AE, Maree A, Tarragona S, Fernandez-Pereira C, Santaera O, Rodriguez Granillo AM, Rodriguez-Granillo GA, Russo-Felssen M, Kukreja N, Antoniucci D, Palacios IF, Serruys PW; ORAR III Investigators.

EuroIntervention. 2009 Jun;5(2):255-64.

PMID:
20449934
4.

Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).

Nienaber CA, Akin I, Schneider S, Senges J, Fetsch T, Tebbe U, Willich SN, Stumpf J, Sabin GV, Silber S, Richardt G, Kuck KH; DES.DE Study Group.

Am J Cardiol. 2009 Nov 15;104(10):1362-9. doi: 10.1016/j.amjcard.2009.06.058. Epub 2009 Sep 26.

PMID:
19892051
5.

Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial).

Amin AP, Reynolds MR, Lei Y, Magnuson EA, Vilain K, Durtschi AJ, Simonton CA, Stone GW, Cohen DJ.

Am J Cardiol. 2012 Sep 15;110(6):765-70. doi: 10.1016/j.amjcard.2012.05.006. Epub 2012 May 30.

PMID:
22651880
6.

Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.

Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J.

Circulation. 2012 Jun 12;125(23):2873-91. doi: 10.1161/CIRCULATIONAHA.112.097014. Epub 2012 May 14.

7.

A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.

Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, McLaurin BT, Solomon SL, Douglas JS Jr, Ball MW, Caputo RP, Jain A, Tolleson TR, Reen BM 3rd, Kirtane AJ, Fitzgerald PJ, Thompson K, Kandzari DE; ENDEAVOR IV Investigators.

J Am Coll Cardiol. 2010 Feb 9;55(6):543-54. doi: 10.1016/j.jacc.2009.08.067.

8.

Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis.

Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F.

BMJ. 2013 Nov 8;347:f6625. doi: 10.1136/bmj.f6625.

9.

Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Restenosis (CEREA-DES).

Ribichini F, Tomai F, Pesarini G, Zivelonghi C, Rognoni A, De Luca G, Boccuzzi G, Presbitero P, Ferrero V, Ghini AS, Marino P, Vassanelli C; CEREA-DES Investigators.

Eur Heart J. 2013 Jun;34(23):1740-8. doi: 10.1093/eurheartj/eht079. Epub 2013 Mar 14.

PMID:
23492671
10.

Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.

Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone GW.

J Am Coll Cardiol. 2013 Aug 6;62(6):496-504. doi: 10.1016/j.jacc.2013.05.022. Epub 2013 Jun 7.

11.

Percutaneous coronary intervention with second-generation paclitaxel-eluting stents versus everolimus-eluting stents in United States contemporary practice (REWARDS TLX Trial).

Waksman R, Ghali M, Goodroe R, Ryan T, Turco M, Ring M, McGarry T, Dobies D, Shammas N, Steinberg DH, Swymelar S, Kaneshige K, Torguson R.

Am J Cardiol. 2012 Oct 15;110(8):1119-24. doi: 10.1016/j.amjcard.2012.05.050. Epub 2012 Jul 3.

PMID:
22762711
12.

Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.

Tamburino C, Barbagallo R, Capodanno D, di Matteo S, Colombo GL, Recchia M, Ciriminna S; Sicilian DES Registry Investigators.

J Cardiovasc Med (Hagerstown). 2009 Apr;10(4):322-9. doi: 10.2459/JCM.0b013e3283276ebb.

PMID:
19430343
13.

Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry.

Ong AT, Daemen J, van Hout BA, Lemos PA, Bosch JL, van Domburg RT, Serruys PW.

Eur Heart J. 2006 Dec;27(24):2996-3003. Epub 2006 Nov 17.

PMID:
17114234
14.

Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.

Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Smits PC, Kaiser C, D'Ascenzo F, Frati G, Mancone M, Genereux P, Stone GW.

J Am Coll Cardiol. 2014 Feb 4;63(4):299-307. doi: 10.1016/j.jacc.2013.09.061. Epub 2013 Nov 6. Review.

15.
16.

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.

Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB.

N Engl J Med. 2007 Mar 8;356(10):998-1008. Epub 2007 Feb 12.

17.

Cost effectiveness of drug-eluting stents as compared with bare metal stents in patients with coronary artery disease.

Wisløff T, Atar D, Sønbø Kristiansen I.

Am J Ther. 2013 Nov-Dec;20(6):596-601. doi: 10.1097/MJT.0b013e3182211a01.

PMID:
21822114
18.

Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction: insights from the TYPHOON trial.

Canoui-Poitrine F, Jeanblanc G, Alberti C, Armoogum P, Cebrian A, Carrié D, Henry P, Teiger E, Slama M, Spaulding C, Durand-Zaleski I.

Appl Health Econ Health Policy. 2009;7(1):19-29. doi: 10.2165/00148365-200907010-00003.

PMID:
19558192
19.
20.

Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents.

Mahmoudi M, Delhaye C, Wakabayashi K, Ben-Dor I, Gonzalez MA, Maluenda G, Gaglia MA Jr, Torguson R, Xue Z, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R.

Am J Cardiol. 2011 Jun 15;107(12):1757-62. doi: 10.1016/j.amjcard.2011.02.330. Epub 2011 Apr 15.

PMID:
21497782

Supplemental Content

Support Center